Issue of Equity and Total Voting Rights

RNS Number : 0578V
Circassia Pharmaceuticals Plc
18 July 2018
 

            18 July 2018

Circassia Pharmaceuticals plc

 

Issue of Equity and Total Voting Rights

 

Circassia Pharmaceuticals plc ("Circassia" or "the Company") (LSE: CIR) announces that, further to the announcement made on 16th July 2018, 23,725,800 Ordinary Shares have been admitted to the premium listing segment of the Official List of the UK Listing Authority and to trading on the London Stock Exchange's main market for listed securities (together, "Admission").

 

In accordance with the requirements of the FCA's Disclosure and Transparency Rule 5.6.1, Circassia confirms that the Company's issued share capital consists of 357,192,062 Ordinary Shares, each with equal voting rights. No shares are held in treasury.

 

The above figure may be used by shareholders as the denominator for the calculations by which they will determine whether they are required to notify their interest, or a change to their interest, in the Company under the FCA's Disclosure and Transparency Rules.

 

For further information, please contact:

 

Circassia Pharmaceuticals plc

 

Julien Cotta, Company Secretary +44 (0) 1865 405560


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
MSCEAAXPFSFPEFF

Companies

Niox Group (NIOX)
UK 100

Latest directors dealings